Jon Blaskovich
Chief Tech/Sci/R&D Officer presso BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.
Profilo
Jon Blaskovich è un direttore delle tecnologie dell'informazione presso la Biohaven Pharmaceutical Holding Co. Ltd. Si è laureato al Rochester Institute of Technology.
Posizioni attive di Jon Blaskovich
| Società | Posizione | Inizio |
|---|---|---|
| BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | Chief Tech/Sci/R&D Officer | - |
| BIOHAVEN LTD. | Chief Tech/Sci/R&D Officer | - |
Precedenti posizioni note di Jon Blaskovich
| Società | Posizione | Fine |
|---|---|---|
Epsilon Data Management LLC
 Epsilon Data Management LLC Advertising/Marketing ServicesCommercial Services Epsilon Data Management LLC provides marketing and data management services. It offers multi channel marketing, technologies and database solutions, strategic consulting, and account management services. The company was founded in 1969 and is headquartered in Irving, TX. | Chief Tech/Sci/R&D Officer | - |
Formazione di Jon Blaskovich
| Rochester Institute of Technology | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| BIOHAVEN LTD. | Health Technology |
| Aziende private | 2 |
|---|---|
Epsilon Data Management LLC
Epsilon Data Management LLC Advertising/Marketing ServicesCommercial Services Epsilon Data Management LLC provides marketing and data management services. It offers multi channel marketing, technologies and database solutions, strategic consulting, and account management services. The company was founded in 1969 and is headquartered in Irving, TX. | Commercial Services |
Biohaven Pharmaceutical Holding Co. Ltd.
 Biohaven Pharmaceutical Holding Co. Ltd. Pharmaceuticals: MajorHealth Technology Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT. | Health Technology |
- Borsa valori
- Insiders
- Jon Blaskovich
